POS0405 INCREASED LEVELS OF CELLULAR ADHESION MOLECULES ARE LINKED TO THE PRESENCE OF INTERSTITIAL LUNG DISEASE IN PATIENTS WITH AUTOIMMUNE DISEASES
Authors: V. Pulito-Cueto, S. Remuzgo-Martínez, F. Genre, B. Atienza-Mateo, V. Portilla, V. M. Mora-Cuesta, D. Iturbe Fernández, L. Lera-Gómez, D. Prieto-Peña, R. Blanco, A. Corrales, O. Gualillo, J. M. Cifrián-Martínez, R. López-Mejías, M. A. González-Gay
Journal: Annals of the Rheumatic Diseases (2022)

Background Intercellular adhesion molecule-1 (ICAM-1) and E-Selectin are adhesion molecules considered as markers of underlying endothelial activity and damage. These molecules are known to play an important role in autoimmune disease (AD) [1]. Accordingly, they may contribute to the development of interstitial lung disease (ILD), one of the main causes of death in patients with AD [2]. In fact, they have been proposed as prognostic biomarkers in idiopathic pulmonary fibrosis (IPF) [3]. However, studies on the role of ICAM-1 and E-Selectin in AD-ILD + are scarce. Objectives To study the role of ICAM-1 and E-Selectin in the pathogenesis of AD-ILD + . Methods Peripheral venous blood was collected from 57 patients with AD-ILD + and three comparative groups: 45 AD-ILD - patients, 21 IPF patients and 21 healthy controls (HC). All the subjects were recruited from the Rheumatology and Pneumology departments of Hospital Universitario Marqués de Valdecilla, Santander, Spain. ICAM-1 and E-Selectin levels were measured in serum samples by enzyme-linked immunosorbent assay. Results Higher levels of ICAM-1 and E-Selectin were found in patients with AD-ILD + compared to AD-ILD - patients (p&lt;0.001 and p=0.001, respectively) and HC (p&lt;0.001 in both cases). Likewise, IPF patients showed increased levels of ICAM-1 and E-Selectin in relation to AD-ILD - patients (p&lt;0.001 and p=0.002, respectively) and HC (p&lt;0.001 in both cases). However, no statistically significant difference in ICAM-1 and E-Selectin concentrations was observed between AD-ILD + and IPF patients. Conclusion Our study suggests that increased levels of ICAM-1 and E-Selectin are associated with the presence of ILD in AD patients. References [1]Int J Mol Sci 2014;15(7):11324-49; [2]Expert Rev Clin Immunol 2018;14(1):69-82; [3]Eur Respir J 2019;54(3):1900295 Acknowledgements VP-C is supported by a pre-doctoral grant from IDIVAL (PREVAL18/01); SR-M is supported by funds of the RETICS Program (RD16/0012/0009) from `Instituto de Salud Carlos III´ (ISCIII), co-funded by the European Regional Development Fund; RL-M is a recipient of a Miguel Servet type I programme fellowship from ISCIII, co-funded by the European Social Fund, `Investing in your future’ (grant CP16/00033). Disclosure of Interests Verónica Pulito-Cueto: None declared, Sara Remuzgo-Martínez: None declared, Fernanda Genre: None declared, Belén Atienza-Mateo: None declared, Virginia Portilla: None declared, Victor Manuel Mora-Cuesta: None declared, David Iturbe Fernández: None declared, Leticia Lera-Gómez: None declared, Diana Prieto-Peña: None declared, Ricardo Blanco Speakers bureau: Abbvie, Pfizer, Roche, Bristol-Myers, Janssen and MSD, Consultant of: Abbvie, Pfizer, Roche, Bristol-Myers, Janssen and MSD, Grant/research support from: Abbvie, MSD and Roche, Alfonso Corrales: None declared, Oreste Gualillo: None declared, Jose Manuel Cifrián-Martínez: None declared, Raquel López-Mejías: None declared, Miguel A González-Gay Speakers bureau: Abbvie, Pfizer, Roche, Sanofi, Lilly, Celgene, MSD, GSK, Grant/research support from: Abbvie, MSD, Janssen, Roche.